Equillium Inc
Change company Symbol lookup
Select an option...
EQ Equillium Inc
TSLA Tesla Inc
OPK OPKO Health Inc
PNW Pinnacle West Capital Corp
ROLL RBC Bearings Inc
GLAD Gladstone Capital Corp
PAC Grupo Aeroportuario del Pacifico SAB de CV
HQDA HQDA Elderly Life Network Corp
MDT Medtronic PLC
DSKYF Daiichi Sankyo Co Ltd
Go

Health Care : Biotechnology |
Company profile

Equillium, Inc. is a biotechnology company. The Company develops products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its initial product candidate, EQ001 (itolizumab), is a clinical-stage, monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cells, or Teff cells. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. EQ001, disease modifying treatment for multiple severe immuno-inflammatory disorders. It plans to initiate a Phase Ib/II clinical trial of EQ001 for the treatment of acute graft-versus-host disease, or aGVHD.

Closing Price
$6.35
Day's Change
0.35 (5.83%)
Bid
--
Ask
--
B/A Size
--
Day's High
7.51
Day's Low
5.99
Volume
(Heavy Day)
Volume:
17,634,609

10-day average volume:
1,767,312
17,634,609

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.